Viking Therapeutics' Stock Soars on Promising Weight-Loss Drug Results

The biotech firm's shares surged after phase II trial results showed significant weight loss, sparking acquisition interest.

Viking Therapeutics' stock more than doubled following impressive phase II trial results for its weight-loss drug, VK2735.
The drug demonstrated up to 15% weight loss in patients over 13 weeks, exceeding expectations and outperforming current market leaders.
Analysts have raised sales estimates and company valuation, citing the drug's potential to disrupt the $100 billion obesity therapy market.
The company announced a $550 million stock offering to fund further development, including a pill version of the weight-loss treatment.
Speculation about potential acquisition by major pharmaceutical companies has intensified, with Pfizer mentioned as a possible suitor.